[go: up one dir, main page]

AU2002231283A1 - Use of p38 inhibitors for the treatment of smoke inhalation - Google Patents

Use of p38 inhibitors for the treatment of smoke inhalation

Info

Publication number
AU2002231283A1
AU2002231283A1 AU2002231283A AU3128302A AU2002231283A1 AU 2002231283 A1 AU2002231283 A1 AU 2002231283A1 AU 2002231283 A AU2002231283 A AU 2002231283A AU 3128302 A AU3128302 A AU 3128302A AU 2002231283 A1 AU2002231283 A1 AU 2002231283A1
Authority
AU
Australia
Prior art keywords
inhibitors
treatment
smoke inhalation
inhalation
smoke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002231283A
Inventor
Don E. Griswold
David C. Underwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002231283A1 publication Critical patent/AU2002231283A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002231283A 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation Abandoned AU2002231283A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24156800P 2000-10-19 2000-10-19
US60/241,568 2000-10-19
PCT/US2001/050429 WO2002032862A2 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation

Publications (1)

Publication Number Publication Date
AU2002231283A1 true AU2002231283A1 (en) 2002-04-29

Family

ID=22911223

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002231283A Abandoned AU2002231283A1 (en) 2000-10-19 2001-10-19 Use of p38 inhibitors for the treatment of smoke inhalation

Country Status (4)

Country Link
EP (1) EP1337250A2 (en)
JP (1) JP2004511542A (en)
AU (1) AU2002231283A1 (en)
WO (1) WO2002032862A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1709965A3 (en) 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
MXPA04009605A (en) * 2002-04-05 2005-01-11 Boehringer Ingelheim Pharma Method of treating mucus hypersecretion.
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
WO2006137421A1 (en) * 2005-06-21 2006-12-28 Kyowa Hakko Kogyo Co., Ltd. Agent for topical administration
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
SG11202003035SA (en) 2017-10-05 2020-04-29 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN109557254B (en) * 2018-11-14 2021-08-03 云南中烟工业有限责任公司 A method for establishing standardized cigarette smoke muzzle exposure method in mice

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235760B1 (en) * 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
WO1999064400A1 (en) * 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38

Also Published As

Publication number Publication date
WO2002032862A3 (en) 2002-08-22
EP1337250A2 (en) 2003-08-27
WO2002032862A2 (en) 2002-04-25
JP2004511542A (en) 2004-04-15

Similar Documents

Publication Publication Date Title
EG22308A (en) Tobacco treatment
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2002258399A1 (en) Use of trail and antiprogestins for treating cancer
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL160853A0 (en) Nicotine containing formulations and use thereof
AU2001249262A1 (en) Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof
ZA200510170B (en) Method of reducing the harmful effects of orally or transdermally delivered nicotine
AU6900201A (en) Breath-controlled therapeutic inhalation device
AU6083899A (en) Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AU2001285747A1 (en) Method for the treatment of tobacco
HUP0302739A3 (en) Method for the treatment of tobacco
GB0004531D0 (en) The treatment of respiratory diseases
HK1083732A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
AU2002231283A1 (en) Use of p38 inhibitors for the treatment of smoke inhalation
AU2001293891A1 (en) New combination for the treatment of asthma
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
PL357812A1 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU7402201A (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU2001274022A1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2908501A (en) Combination therapy for the treatment of inflammatory and respiratory diseases
AU2002215923A1 (en) Use of medicaments